Rockefeller Capital Management’s Kyntra Bio KYNB Stock Holding History

Rockefeller Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1	Closed	–	–	4192
2022 Q1	$0	Hold	1	–	–	﹤0.01%	3923
2021 Q4	$0	Hold	1	–	–	﹤0.01%	3832
2021 Q3	$0	Hold	1	–	–	﹤0.01%	3731
2021 Q2	$0	Sell	1 -1	-50%	-$576	﹤0.01%	3488
2021 Q1	$1K	Sell	2 -2	-50%	-$2.13K	﹤0.01%	3170
2020 Q4	$3K	Hold	4	–	–	﹤0.01%	2550
2020 Q3	$3K	Hold	4	–	–	﹤0.01%	2329
2020 Q2	$4K	Hold	4	–	–	﹤0.01%	2155
2020 Q1	$3K	Buy	+4	New	+$3.98K	﹤0.01%	2090
2019 Q2	–	Sell	-1	Closed	-$2K	–	1759
2019 Q1	$2K	Buy	+1	New	+$1.36K	﹤0.01%	1783
2018 Q3	–	Sell	-80	Closed	-$125K	–	764
2018 Q2	$125K	Hold	80	–	–	﹤0.01%	368
2018 Q1	$92K	Buy	+80	New	+$105K	﹤0.01%	377

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Rockefeller Capital Management's KYNB Position: Q2 2022 in Review

Rockefeller Capital Management sold out of Kyntra Bio (KYNB) in Q2 2022, closing a stake of 1 share.

Rockefeller Capital Management first reported a position in KYNB in Q1 2018 and held it in 12 quarters. The position peaked at $125K in Q2 2018. 150 funds tracked by Wall St. Rank hold KYNB as of Q2 2022.

Rockefeller Capital Management reported no remaining Kyntra Bio position as of Q2 2022 after selling out during the quarter.
Rockefeller Capital Management sold 1 Kyntra Bio share in Q2 2022.
Rockefeller Capital Management first reported a position in Kyntra Bio in Q1 2018 and held it in 12 quarters.
Rockefeller Capital Management's Kyntra Bio position peaked at $125K in Q2 2018.
150 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2022.

Based on Rockefeller Capital Management's 13F filing for Q2 2022, filed 12 Aug 2022.